Hone rebrands testosterone as longevity membership

The real win was not just moving testosterone online, it was turning a stigmatized clinic purchase into an aspirational subscription. Hone packaged a controlled substance inside a workflow that feels closer to a longevity membership than a low T clinic visit, with at home testing, video consults, recurring blood work, and add on treatments. That reframing let it charge premium pricing, lift retention, and expand from TRT into weight loss, women’s hormones, and other cash pay therapies.

• Older low T clinics were usually local, in person, and transactional. Hone made the experience look like modern consumer health, a $45 starter kit, lab results, a FaceTime visit, then a $129 to $149 monthly membership plus meds. That makes the product feel managed and medical, not sketchy and one off.
  1 sacra 2 sacra
• The closest analogue is Ro and Hims with ED, but TRT is stickier and more operationally heavy. Patients need repeat labs and dose changes, so Hone can earn $150 plus average monthly spend with better lifetime value than telehealth products built around generic Viagra or Cialis.
  1 sacra 2 sacra
• The longevity framing also widened the market beyond men who already identified as having low testosterone. Similar to Function Health selling broad biomarker testing as proactive health optimization, Hone sells hormone care into a larger wellness budget, then layers on GLP-1s, metformin, NAD+, and women’s hormone therapy.
  2 sacra 3 sacra 4 sacra

This category is heading toward broader hormone and metabolic memberships, where the company that controls testing, prescribing, and follow up will own the highest value customer relationship. Hone has a head start in that full stack model, but mass market telehealth players are moving in, with Hims set to launch oral testosterone in 2026 and remote prescribing flexibilities extended through December 31, 2026.